New shot could soothe tough eczema for teens and adults
NCT ID NCT07479615
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tests an injectable drug called MG-K10 for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. About 498 participants will receive either MG-K10 or a placebo to see if it safely reduces skin redness, itching, and sores. The goal is to find a new option for those who need more than topical treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MG-K10 (a humanized monoclonal antibody injection)
- What this could lead to
- If successful, this could provide a new treatment option for people with moderate-to-severe atopic dermatitis who don't respond well to current therapies.
- What could go wrong
- This is an early-stage global study; results may not confirm effectiveness or safety. Side effects are possible, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?